JP2014533299A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533299A5
JP2014533299A5 JP2014542393A JP2014542393A JP2014533299A5 JP 2014533299 A5 JP2014533299 A5 JP 2014533299A5 JP 2014542393 A JP2014542393 A JP 2014542393A JP 2014542393 A JP2014542393 A JP 2014542393A JP 2014533299 A5 JP2014533299 A5 JP 2014533299A5
Authority
JP
Japan
Prior art keywords
optionally substituted
cancer
pharmaceutical composition
alkyl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533299A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/064967 external-priority patent/WO2013074594A1/en
Publication of JP2014533299A publication Critical patent/JP2014533299A/ja
Publication of JP2014533299A5 publication Critical patent/JP2014533299A5/ja
Pending legal-status Critical Current

Links

JP2014542393A 2011-11-14 2012-11-14 Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法 Pending JP2014533299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559486P 2011-11-14 2011-11-14
US61/559,486 2011-11-14
PCT/US2012/064967 WO2013074594A1 (en) 2011-11-14 2012-11-14 Combination therapy of hsp90 inhibitors with braf inhibitors

Publications (2)

Publication Number Publication Date
JP2014533299A JP2014533299A (ja) 2014-12-11
JP2014533299A5 true JP2014533299A5 (https=) 2016-01-07

Family

ID=47278530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542393A Pending JP2014533299A (ja) 2011-11-14 2012-11-14 Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法

Country Status (6)

Country Link
US (1) US9402831B2 (https=)
EP (1) EP2780010A1 (https=)
JP (1) JP2014533299A (https=)
AU (1) AU2012339679A1 (https=)
CA (1) CA2854188A1 (https=)
WO (1) WO2013074594A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
US20150352086A1 (en) * 2013-01-07 2015-12-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
KR102416358B1 (ko) 2014-03-20 2022-07-07 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
US20170239351A1 (en) 2014-08-11 2017-08-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
MA40596B1 (fr) 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
DK3300500T3 (da) 2015-05-20 2020-05-18 Amgen Inc Triazolagonister af apj-receptoren
WO2017053537A1 (en) 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3375455A1 (en) * 2017-03-15 2018-09-19 Les Hôpitaux Universitaires de Genève Agents enhancing hur/elav protein levels for use in the treatment of braf-mutated cancers
US10787443B2 (en) 2017-04-28 2020-09-29 Zamboni Chem Solutions Inc. RAF-degrading conjugate compounds
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
WO2025073290A1 (en) * 2023-10-06 2025-04-10 Para Therapeutics, Inc. Vps4 inhibitors and methods of use thereof

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1001992C2 (de) 1954-05-10 1957-07-11 Hoechst Ag Verfahren zur Herstellung von 3, 5-Di-(2'-anthrachinonyl)-4-phenyl-1, 2, 4-triazolen
US2898343A (en) 1957-11-18 1959-08-04 American Cyanamid Co Anthraquinone triazoles
GB928919A (en) 1960-08-16 1963-06-19 Bellon Labor Sa Roger Triazole derivatives and a process for their preparation
US3898272A (en) 1966-05-06 1975-08-05 Bayer Ag Thionosalicylic acid anilides
DE1805156B2 (de) 1968-10-25 1976-01-29 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2- acyloxythionobenzamiden
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4178253A (en) 1977-04-05 1979-12-11 Ciba-Geigy Corporation Corrosion inhibited lubricant compositions
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPS5770820A (en) 1980-10-20 1982-05-01 Haruo Ogura Immunoregulating agent
JPS5910574A (ja) 1982-07-07 1984-01-20 Fujisawa Pharmaceut Co Ltd トリアゾ−ル誘導体およびその製造法
FR2546887B1 (fr) 1983-05-30 1985-08-30 Paris 7 Universite Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624995A (en) 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4740568A (en) 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5006650A (en) 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
DE3729070A1 (de) 1987-09-01 1989-03-09 Bayer Ag Substituierte triazolinone
US5241074A (en) 1988-05-09 1993-08-31 Bayer Aktiengesellschaft Sulphonylaminocarbonyltriazolinones
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5219722A (en) 1990-09-21 1993-06-15 Konica Corporation Silver halide color photographic light-sensitive material
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69330713T2 (de) 1992-03-13 2002-07-04 Merck Sharp & Dohme Ltd., Hoddesdon Imidazol-, triazol- und tetrazolderivate
TW218017B (https=) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
DE4222771A1 (de) 1992-07-10 1994-01-13 Bayer Ag Heterocyclyltriazolinone
DE4234801A1 (de) 1992-10-15 1994-04-21 Bayer Ag Sulfonylaminocarbonyltriazolinone
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4303376A1 (de) 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
DE4303676A1 (de) 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DE4411913A1 (de) 1994-04-07 1995-10-12 Bayer Ag Substituierte Sulfonylaminocarbonyltriazolinone
US5538988A (en) 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5489598A (en) 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3372365B2 (ja) 1994-08-19 2003-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料およびそれを用いた画像形成方法
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
DE19502579A1 (de) 1995-01-27 1996-08-01 Bayer Ag Sulfonylamino(thio)carbonyl-triazolin(thi)one
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
DE19521162A1 (de) 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
DE19525162A1 (de) 1995-07-11 1997-01-16 Bayer Ag Sulfonylamino(thio)carbonylverbindungen
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
DE19540737A1 (de) 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
DE19609059A1 (de) 1996-03-08 1997-09-11 Bayer Ag Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one
ZA974703B (en) 1996-05-30 1997-12-30 Bayer Ag Substituted sulfonylamino(thio)carbonyl compounds.
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE19632945A1 (de) 1996-08-16 1998-02-19 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
JP2001504121A (ja) 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP3788676B2 (ja) 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
US6583090B1 (en) 1998-03-09 2003-06-24 Basf Aktiengesellschaft Hetaryl-substituted benzyl phenyl ethers, method for the production thereof, and their use for combating harmful fungi and animal pests
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000284412A (ja) 1999-03-30 2000-10-13 Fuji Photo Film Co Ltd 熱現像写真材料
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
SE9902387D0 (sv) 1999-06-22 1999-06-22 Astra Ab New pharmaceutically active compounds
US20040110684A1 (en) 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1223932A4 (en) 1999-10-01 2003-01-15 Smithkline Beecham Corp COMPOUNDS AND METHODS
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
AU2001292548B2 (en) 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CA2426762A1 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
CA2440211A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
EP1387678A1 (en) 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
JP2004529188A (ja) 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
EP1397364B1 (en) 2001-05-24 2007-07-25 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
JP4102124B2 (ja) 2001-08-01 2008-06-18 富士フイルム株式会社 ハロゲン化銀乳剤およびハロゲン化銀写真感光材料
WO2003013430A2 (en) 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
WO2003022274A2 (en) 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
BR0214553A (pt) 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
CA2466762A1 (en) 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0207362D0 (en) 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
AU2003277299B2 (en) 2002-04-10 2009-12-10 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
GB0208516D0 (en) 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
JP2006508974A (ja) 2002-11-15 2006-03-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 癌を治療するためのｍｅｋ阻害剤およびカペシタビン（ｃａｐｅｃｉｔａｂｉｎｅ）を含む併用化学療法
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DE10318020A1 (de) 2003-04-19 2004-11-11 Repower Systems Ag Gitterturm für eine Windkraftanlage
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050019918A1 (en) 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
EP1636182A4 (en) 2003-06-12 2008-09-03 Merck & Co Inc PRODRUGS OF INHIBITORS FROM MITOTIC KINESINE
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2536470A1 (en) 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
JP2005084612A (ja) 2003-09-11 2005-03-31 Fuji Photo Film Co Ltd ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料
BRPI0414698A (pt) 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
AU2004284420A1 (en) 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
MXPA06004657A (es) 2003-10-28 2006-06-27 Pharmacia Corp Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP2007527919A (ja) 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
WO2005097758A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
WO2005105077A1 (en) 2004-04-28 2005-11-10 Massachusetts Eye & Ear Infirmary Inflammatory eye disease
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
US20060078494A1 (en) 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
CA2588350A1 (en) 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Anti-mitotic anti-proliferative compounds
US20060235034A1 (en) 2004-11-01 2006-10-19 Nouri Neamati Novel compounds for treatment of cancer and disorders associated with angiogenesis function
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
MX2007010227A (es) 2005-02-25 2007-11-07 Serenex Inc Derivados de tetrahidroindolona y tetrahidroindazolona.
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
RU2007137133A (ru) 2005-03-09 2009-04-20 Ниппон Каяку Кабусики Кайся (Jp) Новый ингибитор hsp90
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
BRPI0605907A2 (pt) 2005-07-06 2009-05-26 Sicor Inc processo aperfeiçoado para a preparação de letrozol
JP5149177B2 (ja) 2005-07-25 2013-02-20 シンタ ファーマシューティカルズ コーポレーション 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
EP1951679B1 (en) 2005-08-18 2015-02-18 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
WO2007094819A2 (en) 2005-08-18 2007-08-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2336625T3 (es) 2006-03-22 2010-04-14 Vertex Pharmaceuticals Incorporated Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos.
EP2450437B1 (en) 2006-04-14 2017-05-17 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
WO2007132867A1 (ja) 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited 癌の予防及び治療剤
DE102006023337A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh Triazolderivate II
TW200806637A (en) 2006-05-25 2008-02-01 Synta Pharmaceuticals Corp Synthesis of triazole compounds that modulate HSP90 activity
US8183384B2 (en) 2006-05-25 2012-05-22 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
AU2012200157B2 (en) 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2007139960A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate hsp90 activity and methods for identifying same
EP2026797A2 (en) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008021364A2 (en) 2006-08-17 2008-02-21 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20110046125A1 (en) 2006-10-19 2011-02-24 Synta Pharmaceuticals Corp. Method for treating infections
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
US8299107B2 (en) 2007-02-08 2012-10-30 Synta Pharmaceuticals Corporation Triazole compounds that modulate HSP90 activity
TW200901960A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US8993608B2 (en) 2007-03-12 2015-03-31 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase II
AU2008232354B9 (en) 2007-03-27 2012-07-26 Synta Pharmaceuticals Corp. Triazinone and diazinone derivatives useful as Hsp90 inhibitors
EP2157971B1 (en) 2007-04-13 2012-01-11 Rikshospitalet- Radiumhospitalet HF Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
WO2008153730A2 (en) 2007-05-25 2008-12-18 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-met
US8765802B2 (en) 2007-06-12 2014-07-01 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
US20080318241A1 (en) 2007-06-18 2008-12-25 The Regents Of The University Of Michigan Methods and Systems for Detecting Antiangiogenesis
CN101801983B (zh) 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
WO2009099649A1 (en) 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009102446A2 (en) 2008-02-12 2009-08-20 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
US20090232906A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US9156836B2 (en) 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
ES2415234T3 (es) 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
JP2012500013A (ja) 2008-08-18 2012-01-05 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． Ｈｓｐ９０阻害剤に対する感受性
CN105727297A (zh) 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
US20100209929A1 (en) 2009-01-14 2010-08-19 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of jak/stat activity
WO2010138377A1 (en) 2009-05-28 2010-12-02 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
BR112012009215A2 (pt) * 2009-10-19 2019-09-24 Synta Pharmaceuticals Corp "terapia combinada contra o cancer com compostos inibidores de hsp90"
CA2779843A1 (en) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2333103A1 (en) 2009-12-11 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Differential diagnosis and therapy for kinase inhibitors
EP2560641A2 (en) * 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2011146801A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20120064175A1 (en) 2010-05-20 2012-03-15 Synta Pharmaceuticals Corp. HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
WO2011149824A1 (en) * 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012026931A1 (en) 2010-08-25 2012-03-01 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
JP2014503499A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく治療に適した被験体の事前選択
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
US20140005145A1 (en) 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
EP2663305A1 (en) 2011-01-11 2013-11-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
US20140051665A1 (en) 2011-02-24 2014-02-20 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012118632A1 (en) * 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
WO2012155063A1 (en) 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2012162293A1 (en) 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2714033A1 (en) 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2014520808A (ja) 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物を用いた癌の治療
AU2012299177A1 (en) 2011-08-19 2014-04-10 Synta Pharmaceuticals Corp. Combination cancer therapy of HSP90 inhibitor with antimetabolite
US8628752B2 (en) 2011-10-28 2014-01-14 Synta Pharmaceuticals Corp. Methods of identifying HSP90 inhibitors with less ocular toxicity
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2831061A1 (en) 2012-03-28 2015-02-04 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
CA2868323A1 (en) 2012-04-04 2013-10-10 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
AU2013259267A1 (en) 2012-05-10 2014-11-06 Synta Pharmaceuticals Corp. Treating cancer with Hsp90 inhibitory compounds
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
JP2016500689A (ja) 2012-10-19 2016-01-14 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害性化合物を用いた、多発性嚢胞腎疾患の治療
CA2912830A1 (en) 2013-05-21 2014-11-27 Synta Pharmaceuticals Corp. Specific cancer treatment regimens with ganetespib
WO2015109218A1 (en) 2014-01-17 2015-07-23 Synta Pharmaceuticals Corp. Targeted cancer treatment by hsp90 inhibitors ganetespib and nvp-auy922

Similar Documents

Publication Publication Date Title
JP2014533299A5 (https=)
JP2013537229A5 (https=)
JP2013508378A5 (https=)
JP2014507443A5 (https=)
JP2011509949A5 (https=)
JP2008535902A5 (https=)
JP2010241830A5 (https=)
JP2012526148A5 (https=)
JP2016513137A5 (https=)
JP2013516393A5 (https=)
JP2012153722A5 (https=)
JP2014513704A5 (https=)
JP2011515397A5 (https=)
JP2012505235A5 (https=)
JP2013523756A5 (https=)
JP2018524403A5 (https=)
JP2017526662A5 (https=)
JP2012532100A5 (https=)
JP2015531747A5 (https=)
JP2017528475A5 (https=)
JP2013502423A5 (https=)
NZ701290A (en) Pyrrolobenzodiazepines
JP2015518008A5 (https=)
JP2013535491A5 (https=)
JP2015520753A5 (https=)